Open access
Open access
Powered by Google Translator Translator

Psychiatry

Cohort Study: Metabolic biomarkers and long-term risk of psychiatric disorders in over 200,000 individuals

27 Apr, 2024 | 18:29h | UTC

Study Design and Population:

This population-based cohort study assessed 211,200 participants from the Apolipoprotein-Related Mortality Risk (AMORIS) cohort, who underwent occupational health screening primarily in the Stockholm region of Sweden from 1985 to 1996. Participants were followed longitudinally, with statistical analysis performed between 2022 and 2023. The study included extensive biomarker measurements such as glucose, triglycerides, and high-density lipoprotein.

 

Main Findings:

The study found significant associations between certain metabolic biomarkers and the risk of developing psychiatric disorders such as depression, anxiety, and stress-related disorders. Specifically, high levels of glucose (HR, 1.30) and triglycerides (HR, 1.15) were linked to an increased risk of these disorders, while high levels of high-density lipoprotein (HR, 0.88) were associated with a reduced risk. These findings held true across both genders and all disorders tested, with nested case-control analyses confirming these trends.

 

Implications for Practice:

The study suggests that metabolic dysregulation, as indicated by specific biomarkers, may either increase the risk or be a marker of increased risk for the development of common psychiatric disorders. These findings support the potential for closer monitoring and follow-up of individuals with abnormal metabolic profiles to aid in the prevention and early diagnosis of psychiatric conditions.

 

Reference (free full-text):

Chourpiliadis, C. et al. (2024). Metabolic Profile and Long-Term Risk of Depression, Anxiety, and Stress-Related Disorders. JAMA Network Open, 7(4), e244525. DOI: 10.1001/jamanetworkopen.2024.4525


RCT | Field sobriety tests display insufficient accuracy for detecting THC-specific driving impairment

11 Aug, 2023 | 15:14h | UTC

Evaluation of Field Sobriety Tests for Identifying Drivers Under the Influence of Cannabis: A Randomized Clinical Trial – JAMA Psychiatry

See also: Visual Abstract

News Release: Can field sobriety tests identify drivers under the influence of cannabis? – University of California – San Diego

Commentary: Trained Officers Using Current Field Sobriety Tests May Misclassify Cannabis-Impaired Drivers – Psychiatric News Alert

 

Commentary on Twitter

 


Review | Adverse effects of antidepressant medications and their management in children and adolescents

9 Aug, 2023 | 15:25h | UTC

Adverse Effects of Antidepressant Medications and their Management in Children and Adolescents – Pharmacotherapy

 


M-A | Absence of evidence for antipsychotics in youth unipolar depression; limited evidence in bipolar depression

9 Aug, 2023 | 15:23h | UTC

Effectiveness of atypical antipsychotics for unipolar and bipolar depression in adolescents and young adults: A systematic review and meta-analysis – Journal of Affective Disorders

 


Cohort Study | Clozapine, but not olanzapine or quetiapine, linked with higher perimyocarditis and heart failure risk

8 Aug, 2023 | 13:14h | UTC

The association between exposure to clozapine, olanzapine, and quetiapine and the outcomes perimyocarditis and heart failure: A population-based cohort study – Psychiatry Research

 


Study | Gastric bypass linked to increased risk of non-alcohol substance use disorder

7 Aug, 2023 | 14:23h | UTC

Non-alcohol substance use disorder after bariatric surgery in the prospective, controlled Swedish Obese Subjects study – Obesity

News Release: Gastric bypass surgery associated with non-alcohol substance use disorder – Obesity – The Obesity Society

 


RCT | 52-week antidepressant adjunctive therapy did not lead to a statistically significant benefit over 8-week therapy in bipolar I depression

4 Aug, 2023 | 12:11h | UTC

Duration of Adjunctive Antidepressant Maintenance in Bipolar I Depression – New England Journal of Medicine (link to abstract – $ for full-text)

News Release: Modern antidepressants may reduce risk of relapse for patients with bipolar depression – University of British Columbia

 

Commentary on Twitter

 


Cohort Study | Increased mortality rates in delirium tremens patients versus alcohol withdrawal or dependence

3 Aug, 2023 | 13:35h | UTC

Mortality and alcohol-related morbidity in patients with delirium tremens, alcohol withdrawal state or alcohol dependence in Norway: A register-based prospective cohort study – Addiction

 


Study | Increasing alcohol-related mortality rates in US women, 1999-2020

3 Aug, 2023 | 13:20h | UTC

Trends in Alcohol-Related Deaths by Sex in the US, 1999-2020 – JAMA Network Open

Commentary: As alcohol-related deaths rise in the US, women are increasingly at risk, study shows – CNN

 


Evidence Review | AA and other 12-step programs outperform CBT for alcohol use disorder

2 Aug, 2023 | 14:05h | UTC

Alcohol dependence: evidence and experience on 12 steps to recovery – Evidently Cochrane

Original study: Alcoholics Anonymous and other 12‐step programs for alcohol use disorder – Cochrane Library

 


Cohort Study | Depression at any life stage linked to increased dementia incidence

2 Aug, 2023 | 13:49h | UTC

Association of Early-, Middle-, and Late-Life Depression With Incident Dementia in a Danish Cohort – JAMA Neurology (link to abstract – $ for full-text)

Commentary: Depression Over Adulthood May Increase Risk of Dementia – Psychiatric News Alert

 


Systematic Review | Organizational changes likely decrease physical restraint usage in long-term care

31 Jul, 2023 | 13:53h | UTC

Interventions for preventing and reducing the use of physical restraints for older people in all long‐term care settings – Cochrane Library

Summary: Interventions for preventing and reducing the use of physical restraints in all long-term care settings – Cochrane Library

 


Phase 2 Trial | Oral orexin receptor 2 agonist shows promise in narcolepsy type 1, but raises hepatotoxic concerns

28 Jul, 2023 | 14:09h | UTC

Oral Orexin Receptor 2 Agonist in Narcolepsy Type 1 – New England Journal of Medicine (link to abstract – $ for full-text)

 

Commentary on Twitter

 


RCT | Zuranolone, a potential rapid-acting oral treatment for severe postpartum depression

27 Jul, 2023 | 13:00h | UTC

Zuranolone for the Treatment of Postpartum Depression – American Journal of Psychiatry (link to abstract – $ for full-text)

Commentary: Postpartum Depression Pill Zuralonone Shows Promise in Women With Severe Symptoms – Psychiatric News Alert

Related: RCT | Zuranolone outperforms placebo in major depressive disorder treatment

 


Mitigating neurological, cognitive, and psychiatric sequelae of COVID-19-related critical illness

26 Jul, 2023 | 13:28h | UTC

Mitigating neurological, cognitive, and psychiatric sequelae of COVID-19-related critical illness – The Lancet Respiratory Medicine

 


Systematic Review | Existing research on post-stroke depression interventions lacks conclusive results

25 Jul, 2023 | 13:37h | UTC

Pharmacological, non‐invasive brain stimulation and psychological interventions, and their combination, for treating depression after stroke – Cochrane Library

Summary: Pharmacological, non-invasive brain stimulation and psychological interventions for treating depression after stroke – Cochrane Library

 


Cohort Study | Increased risk of depression and suicide among people with HIV, especially in the first two years post-diagnosis

24 Jul, 2023 | 13:01h | UTC

Risk of Depression in People With HIV: A nationwide population-based matched cohort study – Clinical Infectious Diseases

 

Commentary on Twitter

 


RCT | Online emotion regulation therapy yields significant reduction in adolescent self-injury

24 Jul, 2023 | 12:39h | UTC

Effect of Internet-Delivered Emotion Regulation Individual Therapy for Adolescents With Nonsuicidal Self-Injury Disorder: A Randomized Clinical Trial – JAMA Network Open

See also: Visual Abstract

News Release: Internet-based therapy effective against self-harm in adolescents – Karolinska Institutes

 


Cohort Study | Bipolar disorder associated with a 6-fold higher mortality risk from external causes

21 Jul, 2023 | 13:29h | UTC

Cause-specific excess mortality after first diagnosis of bipolar disorder: population-based cohort study – BMJ Mental Health

News Release: Bipolar disorder linked to 6-fold heightened risk of early death from external causes – BMJ Newsroom

 


M-A | Adverse effects of antipsychotics on sleep in patients with schizophrenia

18 Jul, 2023 | 13:45h | UTC

Adverse effects of antipsychotics on sleep in patients with schizophrenia. Systematic review and meta-analysis – Frontiers in Psychiatry

 


RCT | Placebo equally effective as cognitive-behavioral therapy and aripiprazole in preventing psychosis transition

18 Jul, 2023 | 13:37h | UTC

Prevention of First-Episode Psychosis in People at Clinical High Risk: A Randomized Controlled, Multicentre Trial Comparing Cognitive-Behavioral Therapy and Clinical Management Plus Low-Dose Aripiprazole or Placebo (PREVENT) – Schizophrenia Bulletin (link to abstract – $ for full-text)

Commentary: Aripiprazole or CBT Not More Effective Than Placebo at Preventing Transition to Psychosis – Neurology Advisor

 


Meta-Analysis | Nearly 6% of first-episode psychosis patients exhibit clinically relevant MRI abnormalities

17 Jul, 2023 | 13:32h | UTC

Prevalence of Neuroradiological Abnormalities in First-Episode Psychosis: A Systematic Review and Meta-analysis – JAMA Psychiatry

News Release: Routine brain scanning may improve clinical care for people with psychosis – University of Oxford

 


Cohort Study | Mental disorders linked to increased cardiovascular events in young patients

17 Jul, 2023 | 13:20h | UTC

Increased cardiovascular events in young patients with mental disorders: a nationwide cohort study – European Journal of Preventive Cardiology (free for a limited period)

News Release: Under 40s with mental health problems have elevated risks of heart attack and stroke – European Society of Cardiology

 


RCT | 4-week course of subcutaneous ketamine shows efficacy in treatment-resistant depression

17 Jul, 2023 | 13:17h | UTC

Efficacy and safety of a 4-week course of repeated subcutaneous ketamine injections for treatment-resistant depression (KADS study): randomised double-blind active-controlled trial – British Journal of Psychiatry

News Release: Ketamine effective for treatment-resistant depression: Clinical trial – University of New South Wales

Related:

RCT | Ketamine non-Inferiority to ECT for nonpsychotic resistant depression

M-A | Electroconvulsive therapy may be superior to ketamine for patients with major depressive episode

RCT | Assessing low-dose ketamine’s antidepressant & antisuicidal effects in patients with treatment-resistant depression

M-A | Efficacy and safety of ketamine vs. electroconvulsive therapy among patients with major depressive episode.

 


Clinical practice guideline for deprescribing opioid analgesics

12 Jul, 2023 | 13:58h | UTC

Clinical practice guideline for deprescribing opioid analgesics: summary of recommendations – Medical Journal of Australia

Related:

RCT | Opioids not more effective than placebo for acute low back and neck pain

Deprescribing considerations for older people in general practice – Australian Journal of General Practice

Deprescribing Strategies for Opioids and Benzodiazepines with Emphasis on Concurrent Use: A Scoping Review – Journal of Clinical Medicine

An Overview of Systematic Reviews and Meta-Analyses on the Effect of Medication Interventions Targeting Polypharmacy for Frail Older Adults – Journal of Clinical Medicine

Physician-led medication reviews in polypharmacy patients treated with at least 12 medications in a type 2 diabetes outpatient clinic: a randomised trial – Diabetic Medicine

RCT | A deprescribing intervention reduced medication burden among older adults in post-acute care

Achieving sustainable healthcare through deprescribing of unnecessary medications: making sense of the evidence – Cochrane Library

Deprescribing medicines in older people living with multimorbidity and polypharmacy: the TAILOR evidence synthesis – Health Technology Assessment

Barriers and facilitators to deprescribing of cardiovascular medications: a systematic review – BMJ Open

A National Modified Delphi Consensus Process to Prioritize Experiences and Interventions for Antipsychotic Medication Deprescribing Among Adult Patients With Critical Illness – Critical Care Explorations

Deprescribing proton pump inhibitors – Australian Journal of General Practice

Medication reviews and deprescribing as a single intervention in falls prevention: a systematic review and meta-analysis – Age and Ageing

Optimizing Medication Use in Older Adults With Rheumatic Musculoskeletal Diseases: Deprescribing as an Approach When Less May Be More – ACP Open Rheumatology

Facing the challenge of polypharmacy when prescribing for older people with cardiovascular disease. A review by the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy – European Heart Journal – Cardiovascular Pharmacotherapy

Deprescribing in Older Adults with Cardiovascular Disease – Journal of the American College of Cardiology

Multimorbidity in Older Adults with Cardiovascular Disease – American College of Cardiology, Latest in Cardiology

Antihypertensive Deprescribing in Older Adults: a Practical Guide – Current Hypertension Reports

How-to guide for medication reviews in older adults with cancer: A Young International Society of Geriatric Oncology and Nursing & Allied Health Interest Group initiative – Journal of Geriatric Oncology

Deprescribing in Palliative Cancer Care – Life

Less is More: Deprescribing Medications in Older Adults with Kidney Disease: A Review – Kidney360

Process evaluation of implementation strategies to reduce potentially inappropriate medication prescribing in older population: A scoping review – Research in Social and Administrative Pharmacy

AGA Clinical Practice Update on De-Prescribing of Proton Pump Inhibitors: Expert Review – Gastroenterology

Development of a Metric to Detect and Decrease Low-Value Prescribing in Older Adults – JAMA Network Open

The MedSafer Study—Electronic Decision Support for Deprescribing in Hospitalized Older Adults: A Cluster Randomized Clinical Trial – JAMA Internal Medicine

Quantifying Anticholinergic Burden and Sedative Load in Older Adults with Polypharmacy: A Systematic Review of Risk Scales and Models – Drugs & Aging

Deprescribing in palliative patients with cancer: a concise review of tools and guidelines – Supportive Care in Cancer

Prescribing practices, patterns, and potential harms in patients receiving palliative care: A systematic scoping review – Exploratory Research in Clinical and Social Pharmacy

A narrative review of evidence to guide deprescribing among older adults – Journal of General and Family Medicine

Polypharmacy, inappropriate prescribing, and deprescribing in older people: through a sex and gender lens – The Lancet Health Longevity

Polypharmacy Management in Older Patients – Mayo Clinic Proceedings

Psychopharmacological Treatment in Older People: Avoiding Drug Interactions and Polypharmacy – Deutsches Ärzteblatt international

Eliminating Medication Overload: A National Action Plan – Lown Institute

International Group for Reducing Inappropriate Medication Use & Polypharmacy (IGRIMUP): Position Statement and 10 Recommendations for Action – Drugs & Aging

Common ED Medication Errors: Polypharmacy – emDocs

Current and future perspectives on the management of polypharmacy – BMC Family Practice

Routine deprescribing of chronic medications to combat polypharmacy – Therapeutic Advances in Drug Safety

Polypharmacy—an Upward Trend with Unpredictable Effects – Deutsches Ärzteblatt international

Clinical Consequences of Polypharmacy in Elderly – Expert Opinion on Drug Safety

 


Stay Updated in Your Specialty

Telegram Channels
Free

WhatsApp alerts 10-day free trial

No spam, just news.